19 March 2019
Visiongain has published a new pharma report Global Asthma & COPD Therapies Marke Report : Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.
The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period.
Despite approaching maturity, there remain several unmet needs in the market. In particular, COPD has long been ignored both by medical practitioners, the general public and also the pharmaceutical industry. As the disease is predicted to become the third-leading cause of death by 2030, this will be an area in which novel therapeutics may bring in significant revenue.
The asthma market is becoming highly competitive and fragmented, but there remain significant areas with unmet needs. Pharmaceutical companies will depend on life cycle management strategies in the immediate future to maintain profits with newer pipeline products becoming available over the forecast period.
The lead analyst commented that "Recent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed. The studies suggest that varying genotypes and phenotypes lead to different patients reacting differently to the same drug. This will drive demand for personalised therapies targeting the needs of each patient subgroup. Drugs paired with tests for biomarkers could become more frequent in the R&D pipeline going forward."
Leading companies featured in this report include AstraZeneca, Boehringer Ingelheim, GSK, Merck, Novartis, Roche, Teva and others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.